Related references
Note: Only part of the references are listed.Evaluation of the New Siemens Tacrolimus Assay on the Dimension EXL Integrated Chemistry System Analyzer: Comparison With an Ultra-Performance Liquid Chromatography-Tandem Mass Spectrometry Method
Anne-Sophie Bargnoux et al.
THERAPEUTIC DRUG MONITORING (2016)
Multi-center analytical evaluation of a novel automated tacrolimus immunoassay
Maria Shipkova et al.
CLINICAL BIOCHEMISTRY (2014)
Measurement and Compartmental Modeling of the Effect of CYP3A5 Gene Variation on Systemic and Intrarenal Tacrolimus Disposition
S. Zheng et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2012)
The Need for Standardization of Tacrolimus Assays
Daniel M. Levine et al.
CLINICAL CHEMISTRY (2011)
Analytical performance characteristics of the Abbott Architect i2000 Tacrolimus assay; comparisons with liquid chromatography-tandem mass spectrometry (LC-MS/MS) and Abbott IMx methods
Barun K. De et al.
CLINICA CHIMICA ACTA (2009)
Opportunities to Optimize Tacrolimus Therapy in Solid Organ Transplantation: Report of the European Consensus Conference
Pierre Wallemacq et al.
THERAPEUTIC DRUG MONITORING (2009)
Multi-site Analytical Evaluation of the Abbott ARCHITECT Tacrolimus Assay
Pierre Wallemacq et al.
THERAPEUTIC DRUG MONITORING (2009)
Metabolism of tacrolimus (FK506) and recent topics in clinical pharmacokinetics
Kazuhide Iwasaki
DRUG METABOLISM AND PHARMACOKINETICS (2007)
Effect of CYP3A5 polymorphism on tacrolimus metabolic clearance in vitro
Y Dai et al.
DRUG METABOLISM AND DISPOSITION (2006)
Novel detection assay by PCR-RFLP and frequency of the CYP3A5 SNPs, CYP3A5*3 and *6, in a Japanese population
S Fukuen et al.
PHARMACOGENETICS (2002)
The genetic determinants of the CYP3A5 polymorphism
E Hustert et al.
PHARMACOGENETICS (2001)
Share Paper
